Clinical and microbiologic characteristics of tcdA-negative variant clostridium difficile infections

BMC Infectious Diseases

Jung Oak Kang¹  Mi-ran Seo²  Hyunjoo Pai²  Jieun Kim³ 

[1]Department of Laboratory Medicine, Hanyang University College of Medicine, Guri, Korea

[2]Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea

[3]Department of Internal Medicine, Hanyang University College of Medicine, Guri, Korea

关键词: ermB gene;    Antimicrobial susceptibility test;    Risk factor;    Clinical outcome;    tcdA-negative variant strain;    Clostridium difficile infection;   

Others  :  1175382
DOI  :  10.1186/1471-2334-12-109

 received in 2011-11-08, accepted in 2012-05-09,  发布年份 2012

【 摘 要 】

Background

The tcdA-negative variant (A^-B⁺) of Clostridium difficile is prevalent in East Asian countries. However, the risk factors and clinical characteristics of A^-B⁺C. difficile infections (CDI) are not clearly documented. The objective of this study was to investigate these characteristics.

Methods

From September 2008 through January 2010, the clinical characteristics, medication history and treatment outcomes of CDI patients were recorded prospectively. Toxin characterization and antibiotic susceptibility tests were performed on stool isolates of C. difficile.

Results

During the study period, we identified 22 cases of CDI caused by tcdA-negative tcdB-positive (A^-B⁺) strains and 105 cases caused by tcdA-positive tcdB-positive (A⁺B⁺) strains. There was no significant difference in disease severity or clinical characteristics between the two groups. Previous use of clindamycin and young age were identified as significant risk factors for the acquisition of A^-B⁺ CDI (OR = 4.738, 95% CI 1.48–15.157, p = 0.009 and OR = 0.966, 95% CI 0.935–0.998, p = 0.038, respectively) in logistic regression.

Rates of resistance to clindamycin were 100% and 69.6% in the A^-B⁺ and A⁺B⁺ isolates, respectively (p = 0.006), and the ermB gene was identified in 17 of 21 A^-B⁺ isolates (81%). Resistance to moxifloxacin was also more frequent in the A^-B⁺ than in the A⁺B⁺ isolates (95.2% vs. 63.7%, p = 0.004).

Conclusions

The clinical course of A^-B⁺ CDI is not different from that of A⁺B⁺ CDI. Clindamycin use is a significant risk factor for the acquisition of tcdA-negative variant strains.

【 授权许可】

   
2012 Kim et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366:1079-1084.
• [2]Clements AC, Magalhaes RJ, Tatem AJ, Paterson DL, Riley TV: Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010, 10:395-404.
• [3]Goorhuis A, Legaria MC, van den Berg RJ, Harmanus C, Klaassen CH, Brazier JS, Lumelsky G, Kuijper EJ: Application of multiple-locus variable-number tandem-repeat analysis to determine clonal spread of toxin A-negative Clostridium difficile in a general hospital in Buenos Aires, Argentina. Clin Microbiol Infect 2009, 15:1080-1086.
• [4]Huang H, Wu S, Wang M, Zhang Y, Fang H, Palmgren AC, Weintraub A, Nord CE: Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes. Int J Antimicrob Agents 2009, 33:339-342.
• [5]Lyerly DM, Krivan HC, Wilkins TD: Clostridium difficile: its disease and toxins. Clin Microbiol Rev 1988, 1:1-18.
• [6]Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ: Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377:63-73.
• [7]Kim H, Riley TV, Kim M, Kim CK, Yong D, Lee K, Chong Y, Park JW: Increasing prevalence of toxin A-negative, toxin B-positive isolates of Clostridium difficile in Korea: impact on laboratory diagnosis. J Clin Microbiol 2008, 46:1116-1117.
• [8]Iwashima Y, Nakamura A, Kato H, Wakimoto Y, Wakiyama N, Kaji C, Ueda R: A retrospective study of the epidemiology of Clostridium difficile infection at a University Hospital in Japan: genotypic features of the isolates and clinical characteristics of the patients. J Infect Chemother 2010, 16:329-333.
• [9]Elliott B, Squire MM, Thean S, Chang BJ, Brazier JS, Rupnik M, Riley T: New types of toxin A-negative, toxin B-positive strains among clinical isolates of Clostridium difficile in Australia. J Med Microbiol 2011, 10:10.
• [10]Komatsu M, Kato H, Aihara M, Shimakawa K, Iwasaki M, Nagasaka Y, Fukuda S, Matsuo S, Arakawa Y, Watanabe M, Iwatani Y: High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection. Eur J Clin Microbiol Infect Dis 2003, 22:525-529.
• [11]Shin BM, Kuak EY, Yoo SJ, Shin WC, Yoo HM: Emerging toxin A-B + variant strain of Clostridium difficile responsible for pseudomembranous colitis at a tertiary care hospital in Korea. Diagn Microbiol Infect Dis 2008, 60:333-337.
• [12]Persson S, Torpdahl M, Olsen KE: New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect 2008, 14:1057-1064.
• [13]Mulvey MR, Boyd DA, Gravel D, Hutchinson J, Kelly S, McGeer A, Moore D, Simor A, Suh KN, Taylor G, et al.: Hypervirulent Clostridium difficile strains in hospitalized patients, Canada. Emerg Infect Dis 2010, 16:678-681.
• [14]Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ: Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009, 53:223-228.
• [15]Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC: Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000, 38:2386-2388.
• [16]O'Connor JR, Johnson S, Gerding DN: Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009, 136:1913-1924.
• [17]World Health Organisation: [http://www.whocc.no/] webciteThe anatomical therapeutic chemical (ATC) and defined daily dosing (DDD) system index 2010.
• [18]Zar FA, Bakkanagari SR, Moorthi KM, Davis MB: A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-307.
• [19]Fujitani S, George WL, Murthy AR: Comparison of Clinical Severity Score Indices for Clostridium difficile Infection. Infect Control Hosp Epidemiol 2011, 32:220-228.
• [20]Clabots CR, Gerding SJ, Olson MM, Peterson LR, Gerding DN: Detection of asymptomatic Clostridium difficile carriage by an alcohol shock procedure. J Clin Microbiol 1989, 27:2386-2387.
• [21]Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmee M: A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998, 36:2240-2247.
• [22]Clinical and Laboratory Standards Institute: Methods for antimicrobial susceptibility testing of Anaerobic bacteria; Approved standard, 7th edition. CLSI document M11-A7, Wayne, PA, USA; 2007.
• [23]Johnson S, Samore MH, Farrow KA, Killgore GE, Tenover FC, Lyras D, Rood JI, DeGirolami P, Baltch AL, Rafferty ME, et al.: Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999, 341:1645-1651.
• [24]Cheknis AK, Sambol SP, Davidson DM, Nagaro KJ, Mancini MC, Hidalgo-Arroyo GA, Brazier JS, Johnson S, Gerding DN: Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005–2007. Anaerobe 2009, 15:230-233.
• [25]Pituch H, Obuch-Woszczatynski P, Wultanska D, Nurzynska G, Harmanus C, Banaszkiewicz A, Radzikowski A, Luczak M, van Belkum A, Kuijper E: Characterization and antimicrobial susceptibility of Clostridium difficile strains isolated from adult patients with diarrhoea hospitalized in two university hospitals in Poland, 2004–2006. J Med Microbiol 2011, 60:1200-1205.
• [26]Chung Y, Chung GT, Seong WK, Oh HB: Molecular Analysis of Clostridium difficile Isolates by Arbitrarily Primed-Polymerase Chain Reaction and Polymerase Chain Reaction-Ribotyping. Korean J Infect Dis 2002, 34:167-175.
• [27]Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, et al.: Toxin B is essential for virulence of Clostridium difficile. Nature 2009, 458:1176-1179.
• [28]Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP: The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467:711-713.
• [29]Alfa MJ, Kabani A, Lyerly D, Moncrief S, Neville LM, Al-Barrak A, Harding GK, Dyck B, Olekson K, Embil JM: Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000, 38:2706-2714.
• [30]Arvand M, Hauri AM, Zaiss NH, Witte W, Bettge-Weller G: Clostridium difficile ribotypes 001, 017, and 027 are associated with lethal C. difficile infection in Hesse, Germany. Euro Surveill 2009, 14:19403.
• [31]Drudy D, Fanning S, Kyne L: Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis 2007, 11:5-10.
• [32]Goorhuis A, Debast SB, Dutilh JC, van Kinschot CM, Harmanus C, Cannegieter SC, Hagen EC, Kuijper EJ: Type-Specific Risk Factors and Outcome in an Outbreak With 2 Different Clostridium difficile Types Simultaneously in 1 Hospital. Clin Infect Dis 2011, 53:860-869.
• [33]Pituch H, Van Belkum A, Van Den Braak N, Obuch-Woszczatynski P, Verbrugh H, Meisel-Mikolajczyk F, uczak M: Recent emergence of an epidemic clindamycin-resistant clone of Clostridium difficile among Polish patients with C. difficile-associated diarrhea. J Clin Microbiol 2003, 41:4184-4187.
• [34]Ackermann G, Degner A, Cohen SH, Silva J, Rodloff AC: Prevalence and association of macrolide-lincosamide-streptogramin B (MLS(B)) resistance with resistance to moxifloxacin in Clostridium difficile. J Antimicrob Chemother 2003, 51:599-603.
• [35]Solomon K, Fanning S, McDermott S, Murray S, Scott L, Martin A, Skally M, Burns K, Kuijper E, Fitzpatrick F, et al.: PCR ribotype prevalence and molecular basis of macrolide-lincosamide-streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical Clostridium difficile isolates. J Antimicrob Chemother 2011, 66:1976-1982.